GlassScriptPhysician profile
Matthew Depaul
NPI 1760761654
$1,707.13
in general payments reported to CMS, 2019-2025
27 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $210 · 2023: $486 · 2024: $289 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $519.16 | 2021-2025 | Proclaim, Eterna |
| Astrazeneca Pharmaceuticals LP | $179.70 | 2023-2025 | Tezspire, Breztri |
| Lilly USA, LLC | $121.23 | 2023-2025 | Amyvid, Zepbound |
| Boston Scientific Corporation | $103.39 | 2024 | |
| Vertos Medical, INC. | $85.93 | 2023-2024 | Mild Device Kit |
| Mylan Specialty L.P. | $65.72 | 2022-2023 | Yupelri |
| Averitas Pharma INC. | $57.01 | 2023-2025 | Qutenza |
| Nevro Corp. | $50.04 | 2021-2023 | Senza |
| Harmony Biosciences LLC | $47.61 | 2023 | Wakix |
| Ucb, INC. | $46.00 | 2021 | |
| Genentech USA, INC. | $40.64 | 2025 | Xolair |
| Relievant Medsystems, INC. | $38.62 | 2021 | |
| Amgen INC. | $34.06 | 2023-2024 | Tezspire, Aimovig |
| Medtronic, INC. | $32.67 | 2022-2023 | Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $29.95 | 2025 | Evoke |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $26.71 | 2022 | |
| Biodelivery Sciences International, INC. | $26.08 | 2021 | |
| Stimwave Technologies Incorporated | $24.52 | 2021 | |
| Si-Bone, INC. | $23.89 | 2025 | |
| Genzyme Corporation | $22.16 | 2025 | |
| Eisai INC. | $21.75 | 2022 | |
| Glaxosmithkline, LLC. | $21.46 | 2024 | Arexvy, Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $21.20 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.55 | 2023 | Nuedexta |
| Baxter Healthcare | $20.02 | 2023 | Hillrom - Life 2000 Ventilation System |
| Avanir Pharmaceuticals, INC. | $15.08 | 2022 | |
| Hikma Pharmaceuticals USA | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Depaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.